Home/Filings/4/0001181431-07-048135
4//SEC Filing

ENCORIUM GROUP INC 4

Accession 0001181431-07-048135

CIK 0000856569operating

Filed

Jul 29, 8:00 PM ET

Accepted

Jul 30, 2:42 PM ET

Size

9.0 KB

Accession

0001181431-07-048135

Insider Transaction Report

Form 4
Period: 2007-07-25
Transactions
  • Exercise/Conversion

    stock option

    2007-07-2548,0990 total
    Exercise: $2.57From: 2006-11-01Exp: 2009-01-31common stock (48,099 underlying)
  • Exercise/Conversion

    common stock

    2007-07-25$2.57/sh+48,099$123,61448,099 total
Holdings
  • common stock

    (indirect: managing director of NTGLT Pharma BVBA)
    273,403
Footnotes (4)
  • [F1]Prior to the Company's acquisition of Remedium on November 1, 2006, Mr. Manninen held an option to purchase 120 shares of Remedium. Pursuant to the terms of an option exchange agreement, upon the consummation of the Company's acquisition of Remedium on November 1, 2006, the option held by Mr. Manninen remained outstanding. Upon exercise, however, Mr. Manninen became entitled to receive approximately 400.82 Encorium shares for each Remedium share otherwise issuable upon the exercise of a Remedium option (or approximately 48,099 shares of Encorium stock) at an excercise price of 750 EUR per Remedium share. The EUR 750 exercise price per Remedium share represented an exercise price per Encorium share of $2.57, based on the exchange rate into the U.S. Dollar of the Euro designated by the Federal Reserve Bank of New York as of July 25, 2007.
  • [F2]See Footnote 1.
  • [F3]See Footnote 1.
  • [F4]See Footnote 1.

Issuer

ENCORIUM GROUP INC

CIK 0000856569

Entity typeoperating
IncorporatedNV

Related Parties

1
  • filerCIK 0000856569

Filing Metadata

Form type
4
Filed
Jul 29, 8:00 PM ET
Accepted
Jul 30, 2:42 PM ET
Size
9.0 KB